These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34853104)

  • 1. Disparities by sex in P2Y
    Hickson RP; Kucharska-Newton AM; Rodgers JE; Sleath BL; Fang G
    BMJ Open; 2021 Dec; 11(12):e050236. PubMed ID: 34853104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal P2Y
    Hickson RP; Kucharska-Newton AM; Rodgers JE; Sleath BL; Fang G
    Am Heart J Plus; 2023 Dec; 36():. PubMed ID: 38487715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-practice gaps in P2Y
    Falster MO; Schaffer AL; Wilson A; Nasis A; Jorm LR; Hay M; Leeb K; Pearson SA; Brieger D
    Intern Med J; 2022 Feb; 52(2):249-258. PubMed ID: 32840951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy with a P2Y
    Chiarito M; Sanz-Sánchez J; Cannata F; Cao D; Sturla M; Panico C; Godino C; Regazzoli D; Reimers B; De Caterina R; Condorelli G; Ferrante G; Stefanini GG
    Lancet; 2020 May; 395(10235):1487-1495. PubMed ID: 32386592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.
    Valgimigli M; Gragnano F; Branca M; Franzone A; Baber U; Jang Y; Kimura T; Hahn JY; Zhao Q; Windecker S; Gibson CM; Kim BK; Watanabe H; Song YB; Zhu Y; Vranckx P; Mehta S; Hong SJ; Ando K; Gwon HC; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Jüni P; Mehran R
    BMJ; 2021 Jun; 373():n1332. PubMed ID: 34135011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abbreviated Dual Antiplatelet Therapy Followed by P2Y
    Kumar A; Shariff M; Doshi R; Vaz IP
    Am J Cardiovasc Drugs; 2020 Aug; 20(4):355-361. PubMed ID: 31784888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.
    Wang TY; Kaltenbach LA; Cannon CP; Fonarow GC; Choudhry NK; Henry TD; Cohen DJ; Bhandary D; Khan ND; Anstrom KJ; Peterson ED
    JAMA; 2019 Jan; 321(1):44-55. PubMed ID: 30620370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis.
    Ho AC; Egolum U; Parker S; Dimmel J; Hawkins A; Ling H
    Clin Drug Investig; 2020 Sep; 40(9):799-808. PubMed ID: 32661914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy.
    Ho MY; Chen PW; Feng WH; Su CH; Huang SW; Cheng CW; Yeh HI; Chen CP; Huang WC; Fang CC; Lin HW; Lin SH; Hsieh IC; Li YH
    PLoS One; 2021; 16(5):e0251109. PubMed ID: 33979377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Dual-Antiplatelet Therapy After Myocardial Infarction Among Patients With Chronic Kidney Disease.
    Rymer JA; Kaltenbach LA; Doll JA; Messenger JC; Peterson ED; Wang TY
    J Am Heart Assoc; 2019 May; 8(10):e012236. PubMed ID: 31070112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
    Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
    JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention.
    Luo L; Fu M; Li Y; Chen Z; Yu J; Luo J; Hu S; Tu L; Xu X
    Clin Cardiol; 2020 Mar; 43(3):235-241. PubMed ID: 31777973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there Sex-related Outcome Difference According to oral P2Y12 Inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients.
    Brown O; Rossington J; Buchanan GL; Patti G; Hoye A
    Curr Vasc Pharmacol; 2019; 17(2):191-203. PubMed ID: 29359672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study.
    Kang J; Han JK; Ahn Y; Chae SC; Kim YJ; Chae IH; Hur SH; Seong IW; Chae JK; Cho MC; Seung KB; Jeong MH; Yang HM; Park KW; Kang HJ; Koo BK; Kim HS;
    Thromb Haemost; 2018 Mar; 118(3):591-600. PubMed ID: 29534250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint.
    Wernly B; Rezar R; Gurbel P; Jung C
    J Thromb Thrombolysis; 2020 Jan; 49(1):173-176. PubMed ID: 31686298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.
    Giacoppo D; Matsuda Y; Fovino LN; D'Amico G; Gargiulo G; Byrne RA; Capodanno D; Valgimigli M; Mehran R; Tarantini G
    Eur Heart J; 2021 Jan; 42(4):308-319. PubMed ID: 33284979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.
    Khan SU; Singh M; Valavoor S; Khan MU; Lone AN; Khan MZ; Khan MS; Mani P; Kapadia SR; Michos ED; Stone GW; Kalra A; Bhatt DL
    Circulation; 2020 Oct; 142(15):1425-1436. PubMed ID: 32795096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.